Posted by Michael Wonder on 13 Feb 2024
CAN-3110 receives FDA fast track designation for treatment of recurrent high-grade glioma
13 February 2024 - Candel Therapeutics today announced that the US FDA granted fast track designation for CAN-3110 -- a first in class, replication competent herpes simplex virus-1 oncolytic viral immunotherapy candidate – for the treatment of patients with recurrent high-grade glioma to improve overall survival.
CAN-3110 is designed with dual activity for oncolysis and immune activation in a single therapeutic.
